Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

aTyr Pharma (LIFE)

(Delayed Data from NSDQ)

$NA USD

0 (0.00%)

Updated Dec 31, 1969 06:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 34% (84 out of 248)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

aTyr Pharma, Inc. [LIFE]

Reports for Purchase

Showing records 101 - 120 ( 174 total )

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

06/30/2020

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

06/29/2020

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

06/29/2020

Pages: 5

Register Now to Join Our Call with aTyr''s CEO Tomorrow at 10am ET

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

06/26/2020

Pages: 5

Join Our Call with aTyr''s CEO to Discuss COVID, Cancer - More - June 30th

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

06/24/2020

Pages: 8

Significant Progress Being Made; ATYR1923 Positioning Making Waves

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

06/23/2020

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

06/23/2020

Pages: 6

AACR Highlights aTyr''s Progress Towards IND for NRP2 mAb in Solid Tumors

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

06/19/2020

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

06/18/2020

Pages: 5

ATYR-1923 Could Possibly Prevent COVID-19 Entry Into Cells - Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

06/16/2020

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

06/15/2020

Pages: 5

aTyr Announces the Dosing of the First Patient in its COVID-19 Trial

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

05/20/2020

Pages: 12

AACR Abstracts and Meeting Planner

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

05/14/2020

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

05/14/2020

Pages: 6

1Q20 Results; Sarcoidosis Study Prepped for Strong Restart as COVID-19 Study Gets Going

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

05/13/2020

Pages: 6

1Q20 Update: Smartly Navigating COVID

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

05/01/2020

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

04/30/2020

Pages: 6

ATYR1923 Is Another Shot on Goal in the Fight Against COVID-19

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

04/23/2020

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

04/22/2020

Pages: 7

Strong Case For ATYR1923 In Severe Respiratory Complications of COVID-19

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 25.00

Research Provided by a Third Party

Company: aTyr Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

04/21/2020

Pages: 7

ATYR1923 Brings the Power of Re-Setting the Immune System Against COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party